



## GUJARAT TERCE LABORATORIES LIMITED

4 February 2026

To,  
BSE Limited  
(Security Code: 524314)  
Phiroze Jeejeeboy Towers,  
Dalal Street, Fort,  
Mumbai- 400 001.

Dear Sirs,

**Sub: Outcome of the Board Meeting held on 4 February 2026 – Unaudited Standalone Financial Results of the Company for the third quarter and nine months ended 31 December 2025 - Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")**

**Ref: Intimation of Board Meeting vide letter dated 28 December 2025**

We hereby inform you that, in compliance with Regulation 30 read with Schedule III, Regulation 33 and other applicable provisions of the SEBI Listing Regulations, the Board of Directors of Gujarat Terce Laboratories Limited ("the Company"), at their Meeting held today viz. Wednesday, 4 February 2026, has inter-alia, approved Unaudited Standalone Financial Results of the Company for the third quarter and nine months ended 31 December 2025, subjected to Limited Review of the Statutory Auditor of the Company.

In this regard, please find enclosed the following documents prepared in compliance with Regulations 33 and 47 (as applicable) of the SEBI Listing Regulations:

1. Unaudited Standalone Financial Results for the third quarter and nine months ended 31 December 2025, notes thereon;
2. Unmodified Limited Review Report on the Unaudited Standalone Financial Results for the third quarter and nine months ended 31 December 2025, issued by the Company's Statutory Auditor – Shah Doshi Patel & Associates LLP (Formerly known as M.A. Shah & Co.);
3. Extract of the newspaper publication of the Unaudited Standalone Financial Results for the third quarter and nine months ended 31 December 2025 in prescribed format to be published in print and electronic versions of the newspapers.

The Meeting of the Board of Directors of the Company commenced at 3:00 p.m. (IST) and concluded at 4:05 p.m. (IST).



## **GUJARAT TERCE LABORATORIES LIMITED**

This intimation is also being uploaded on the website of the Company and can be accessed at the weblink:  
<https://www.gujaratterce.in/financial-results/>

Thanking you

**For Gujarat Terce Laboratories Limited**

ASHKA  
SOLANKI

Digitally signed by  
ASHKA SOLANKI  
Date: 2026.02.04  
16:10:37 +05'30'

**Ms. Ashka Solanki**  
**Company Secretary**  
*Enclosures: As above*



**Regd. Office & Factory :** 122/2 Ravi Estate, Bileshwarpura,  
Chhatral, Ta. : Kalol, Dist. : Gandhinagar (Guj.) INDIA.  
Ph.: 02764-233182 ● E.mail : gtl.factory@gmail.com

**Admn. Office :** D/801 & 802, The First, Behind Keshavbaug Party Plot,  
Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat.(INDIA) ● Ph.: 079-48933701  
E.mail : ho@gujaratterce.com ● Web. : www.gujaratterce.com

**CIN:L24100GJ1985PLC007753**



## GUJARAT TERCE LABORATORIES LIMITED

Statement of Unaudited standalone Financial Results for the Quarter and Nine Months ended 31st December, 2025							
Sr. No.	Particulars	[Rs. in Lakhs except per share detail]					
		Quarter ended			Nine Months ended		Year ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		Un Audited	Unaudited	Un Audited	Un Audited	Un Audited	Audited
1		2	3	4	5	6	7
I.	Revenue from operations	1,229.35	1,292.63	1,268.08	3,607.34	3,787.08	5,019.52
II.	Other income	12.67	5.48	6.73	26.24	22.11	30.78
III.	<b>Total Revenue (I+II)</b>	<b>1,242.02</b>	<b>1,298.11</b>	<b>1,274.81</b>	<b>3,633.58</b>	<b>3,809.18</b>	<b>5,050.30</b>
IV.	<b>Expenses:</b>						
	a) Cost of Material consumed	208.39	129.93	188.38	536.70	608.70	914.31
	b) Purchase of stock in trade	283.40	274.78	284.44	817.17	747.45	1,014.85
	c) Changes in inventories of finished goods, WIP and stock in trade.	(41.40)	26.93	(24.63)	(29.78)	(15.90)	(38.14)
	d) Employees benefits expenses	403.29	416.60	397.73	1,194.75	1,202.35	1,618.93
	e) Finance Costs	3.99	6.50	8.45	15.42	34.68	41.54
	f) Depreciation and amortisation exp.	9.61	9.62	9.53	28.84	28.21	38.46
	g) Other Expenses	261.93	255.45	313.14	787.86	961.49	1,121.31
	<b>Total Expenses</b>	<b>1,129.21</b>	<b>1,119.81</b>	<b>1,177.04</b>	<b>3,350.96</b>	<b>3,566.98</b>	<b>4,711.26</b>
V	<b>Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV )</b>	<b>112.81</b>	<b>178.30</b>	<b>97.77</b>	<b>282.62</b>	<b>242.20</b>	<b>339.04</b>
VI	Exceptional items.	-	-	-	-	-	-
VII	<b>Profit/(Loss) before extraordinary items and Tax (V-VI)</b>	<b>112.81</b>	<b>178.30</b>	<b>97.77</b>	<b>282.62</b>	<b>242.20</b>	<b>339.04</b>
VIII	Extraordinary items	-	-	-	-	-	-
IX	<b>Profit/(Loss) before Tax ( VII-VIII)</b>	<b>112.81</b>	<b>178.30</b>	<b>97.77</b>	<b>282.62</b>	<b>242.20</b>	<b>339.04</b>
X	<b>Tax Expenses</b>						
	1) Current Tax	34.03	44.04	-	77.71	-	16.36
	2) Deferred Tax	2.67	(6.06)	(3.03)	(6.14)	0.94	78.84
	3) Income-Tax of Earlier Year ( Refer Note 4)	-	-	-	-	-	341.71
XI	<b>Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>76.11</b>	<b>140.32</b>	<b>100.80</b>	<b>211.05</b>	<b>241.26</b>	<b>(97.87)</b>
XII	<b>Other Comprehensive Income</b>						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	(2.55)	0.04	-	(1.12)	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.50	-	-	0.14	-	-
XIII	<b>Other Comprehensive Income for the period, net of tax</b>	<b>(2.05)</b>	<b>0.04</b>	<b>-</b>	<b>(0.98)</b>	<b>-</b>	<b>-</b>
XIV	<b>Total Comprehensive Income for the period (XI+XII)</b>	<b>74.06</b>	<b>140.36</b>	<b>100.80</b>	<b>210.07</b>	<b>241.26</b>	<b>(97.87)</b>
XV	<b>Paid up Equity Capital ( at par value of Rs. 10 each)</b>	<b>779.13</b>	<b>742.03</b>	<b>742.03</b>	<b>779.13</b>	<b>742.03</b>	<b>742.03</b>
XVI	<b>Earning per equity share</b>						
	a ) Basic	0.95	1.89	1.36	2.70	3.25	(1.31)
	b ) Diluted	0.95	1.80	1.29	2.70	3.10	(1.26)
	(See accompanying notes to the Financial Results)						
<b>Notes:</b>							
1 The above Unaudited Standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on February 04, 2025.							
2 The Limited Review Report for the quarter and nine months ended year ended on 31.12.2025 has been carried out by the statutory auditor, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.							
3 The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these Unaudited financial results of the company for the quarter ended 31.12.2025 has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.							
4 The Company is operating in single (Pharmaceutical) segment, so above Unaudited Financial Results are for single segment only.							
5 The figures of the previous quarter / periods has been regrouped/reclassified, wherever necessary.							
Place: Ahmedabad							
Date: 04/02/2026							
For, Gujarat Terce Laboratories Limited							
 							
Aalap Prajapati							
Managing Director & CEO							
DIN: 08088327							



**Limited Review Report for unaudited standalone quarterly results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.**

We have reviewed the accompanying statement of unaudited financial results of Gujarat Terce Laboratories Limited for the quarter ended on December, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Date:** 04 Feb 2026

**Place:** Anand

Param  
Pramesh Doshi  
Digitally signed by  
Param Pramesh Doshi  
Date: 2026.02.04  
14:50:03 +05'30'

**For, Shah Doshi Patel & Associates LLP**  
**Chartered Accountants**

**Param Doshi, FCA**  
**(Partner)**

**(Mem. No. 185648)**

**UDIN: 26185648XXORAK2322**